Key facts
- Notable investors include Nagoya Institute of Technology, Neuroceuticals, Osaka Metropolitan University.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for WiON
- ·The full record, as it builds
Funding rounds
No funding rounds for WiON are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About WiON
Developer of wireless neuromodulation medical devices and applications designed to provide implantable stimulation therapies for autonomic nervous system conditions. The company integrates wireless monitoring and nerve stimulation control, optimized in-body stimulation coils, and battery-less implantable device architectures developed through academic and clinical collaborations, enabling healthcare providers and research institutions to implement on-demand vagus nerve and related neuromodulation therapies with controlled stimulation parameters and long-term, minimally invasive patient management.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2024
- Website
- wion.jp/
- Ownership
- Privately Held (backing)
WiON doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in WiON shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on WiON in its N-PORT filings yet. We sweep new filings monthly.